My name is Liz Dixon, and I'm the CFO at Tristel plc. Today, we've released our preliminary results for the year ending 30th of June 2023. We're reporting 22% revenue growth, which has come from all areas of the business, and 37% profit growth. We will pay a final dividend of 7.88p on the 22nd of December, making our full-year payout 10.5p, a 10% increase on last year, and we've changed our dividend policy to increase annually by a minimum of 5%. In June, we received clearance from the U.S. FDA to sell Tristel ULT, our high-level disinfecting foam for ultrasound, and have made first sales of the product in the United States. In addition, our ophthalmic high-level disinfectant, Duo OPH, is now selling in Canada, and we've submitted to Health Canada the dossier for Tristel ULT. We have a pipeline of new products in development and making their way to market. So all in all, we have a significant growth opportunity ahead of us, and in this set of results, we are delivering upon our growth plan. We remain profitable, cash generative, and debt-free, and we believe we have a very exciting future ahead of us. I hope to see you during our institutional and private shareholder presentations over the course of this week. Thank you.